#Sweden #Gothenburg #revenue growth #Zinzino #Faun Pharma

Zinzino AB Reports Preliminary Sales Results for April 2026

In an exciting announcement, Zinzino AB (publ) disclosed its preliminary sales report for April 2026, highlighting a significant revenue increase of 22%. This surge brought the total revenue for the month to SEK 300.8 million, up from SEK 246.6 million in April of the previous year. The overall group revenue, which includes sales from Faun Pharma, also showed a remarkable 21% growth, reaching SEK 305.4 million for the period.

Revenue Breakdown by Regions

Zinzino's impressive performance can be seen across various global markets. A closer look at the regional sales figures reveals marked changes:

• - Nordics: Sales grew by 5%, totaling SEK 24.6 million.
• - Central Europe: Showed a robust increase of 37%, reaching SEK 88.8 million.
• - East Europe: Sales decreased slightly by 4%, culminating in SEK 26.1 million.
• - Southwest Europe: Reported a 14% increase to SEK 49.9 million.
• - Baltics: Witnessed a growth of 12% with SEK 9.5 million.
• - North America: Exceptional growth of 36% brought sales to SEK 70.4 million.
• - South America: A staggering increase of 471%, swelling sales to SEK 4 million.
• - Asia-Pacific: Growth remained steady at 2%, totaling SEK 25.6 million.
• - Africa: Increased sales by 27% to SEK 1.9 million.

This strong performance, particularly in Central and North America, indicates Zinzino's expanding influence within the global market.

Accumulated Revenue Growth

From January to April 2026, Zinzino accumulated revenues rose by 26%, reaching a total of SEK 1,227.5 million, compared to SEK 976.3 million during the same period last year. This figure frames a positive outlook for the company's growth trajectory as it taps into emerging markets and strengthens its product offerings.

Challenges Faced by Faun Pharma

While Zinzino's overall sales figures soar, it's important to note that Faun Pharma reported external sales that dropped from SEK 6.1 million to SEK 4.6 million, reflecting a decrease of 25%. This indicates potential challenges for Faun Pharma, necessitating strategies to recover and enhance its sales figures in the upcoming quarters.

Future Outlook

Zinzino's upward trend illustrates the brand's resilience and adaptability in a competitive landscape. With a 21% increase in group sales, the company sets the stage for potential future growth, fueled by the positive reception of its product range across diverse markets. As they continue to innovate and react promptly to market demands, stakeholders can remain optimistic about Zinzino's future performance.

In conclusion, Zinzino AB's impressive sales figures for April 2026 exemplify its successful strategy in growing its market footprint and revenue. As the company navigates the challenges posed by decreasing sales in specific sectors, the overall upward momentum suggests a promising outlook for the remainder of the financial year.

For further details, please contact:

• - Dag Bergheim Pettersen, CEO - +47 (0) 932 25 700
• - Fredrik Nielsen, CFO - +46 (0) 707 900 174